Bayer's Restructuring Arithmetic: 14,000 Jobs Cut as a $7.25 Billion Legal Settlement Waits on the Calendar

Bayer shares climb 76% in a year despite glyphosate litigation delay; Q2 EBITDA beats estimates, net debt reduction accelerates.

The numbers tell two very different stories at Bayer right now. The Leverkusen-based conglomerate has eliminated more than 14,000 positions under its restructuring program, even as its share price climbs toward levels not seen in a year. On Tuesday, the stock traded at 48.83 euros, up 2.7 percent from Monday's close of 47.55 euros — a move that keeps the equity comfortably above its 50-day moving average of 46.02 euros.

Investors have clearly warmed to the direction of travel. The shares have gained 32 percent since the start of the year and 76 percent over the past twelve months, though they remain 9.3 percent below the 52-week high of 53.86 euros reached on July 3. The gap to that peak is a reminder that the company's most persistent overhang — the glyphosate litigation — has yet to be fully retired.

A Court Date That Keeps Moving

The fairness hearing that would grant final approval to Bayer's 7.25 billion US dollar settlement of the Roundup claims has been postponed again. Originally scheduled for August 19, the hearing will now take place on September 14 before a court in Missouri. The delay, announced by Bayer nearly two weeks ago, is intended to allow time to process withdrawal requests from claimants who initially opted out of the class settlement but may now be reconsidering in light of the recent US Supreme Court ruling.

This is the second time the calendar has shifted. The hearing had previously been moved from July 9 at the request of both parties. Market observers have characterized the latest postponement as neutral to mildly positive, reasoning that additional time gives affected claimants the opportunity to make a more considered choice about whether to join or exit the settlement.

For shareholders, the practical consequence is straightforward: the definitive closing of the legal chapter that has weighed on the stock for years remains just out of reach, even though the Supreme Court's decision had already removed a significant obstacle.

Operating Momentum Beneath the Legal Noise

The share price reaction suggests the market has largely priced in the gradual de-escalation of the legal risk. The underlying business performance supports that confidence. In the second quarter, Bayer generated revenue of 10.872 billion euros, a like-for-like increase of 2.2 percent. Adjusted EBITDA rose 1.9 percent to 2.144 billion euros, comfortably ahead of the analyst consensus of roughly 1.94 billion euros. The bottom line swung from a loss of 199 million euros in the year-earlier quarter to a profit of 219 million euros.

The agricultural division, Crop Science, led the improvement with adjusted earnings up 30.2 percent. Pharmaceuticals, by contrast, weighed on the group with a 3.6 percent decline in earnings, reflecting higher marketing spending on newly launched drugs. Core earnings per share fell 16.7 percent to 0.95 euros.

Debt Reduction Accelerates

The restructuring effort extends beyond headcount. Bayer now expects net debt to land between 29 and 30 billion euros, an improvement on the previously communicated range of 32 to 33 billion euros. As of June 30, net financial debt stood at 33.647 billion euros, up 3.5 percent from the end of March.

The faster-than-expected deleveraging has been helped by a series of financing moves. Just over three weeks ago, Bayer placed dollar-denominated bonds worth five billion US dollars with maturities ranging from five to thirty years — an issuance that was multiple times oversubscribed. In mid-July, the company struck a deal with Apollo Global that secures three billion euros in equity for its hormonal coil business LARC, while Bayer retains majority control and operational oversight. That transaction is expected to close in the third quarter of 2026.

Spending While Saving

The cost-cutting program has not halted selective investment. On May 6, Bayer announced the acquisition of Perfuse Therapeutics, a US biotech focused on ophthalmology that is developing a treatment for glaucoma. The deal, worth up to 2.45 billion dollars, signals an intent to build out the pipeline in new therapeutic areas even as the broader organization tightens its belt.

The juxtaposition is stark: more than 14,000 jobs eliminated on one side, targeted bets on future growth on the other. It is a trade-off the workforce is bearing, but one that investors have so far rewarded.

What Comes Next

The immediate focus now shifts to the September 14 hearing and, beyond that, to the third-quarter results scheduled for November 3. The open question in the meantime is how many of the original opt-out claimants will reverse their decision in light of the Supreme Court's ruling — and whether that ultimately smooths the path to approval. For a company that has spent years trying to draw a line under its legal exposure, the answer cannot come soon enough.